Quantum Genesis AI Corp. (OTC: QGAI) released a statement on May 19, 2026, to clarify its relationship with Quantumzyme LLP, a separate entity based in Bengaluru, India, which is not a subsidiary or affiliate of the company. The clarification addresses prior press releases from November 5, 2025, and February 12, 2026, that referenced scientific publications in the enzyme engineering and biocatalysis field. Those publications identified Quantumzyme LLP and reflected researchers' affiliations at the time of submission. The company now seeks to distinguish Quantumzyme from itself and provide context regarding intellectual property rights.
The statement explains that scientific publications arising from research by CEO Naveen Kulkarni appropriately show his affiliations at the time of research. According to an Asset Purchase Agreement dated February 21, 2023, Kulkarni transferred to Quantum Genesis AI certain intellectual property, know-how, methodologies, and research materials related to the company's core enzyme engineering and biocatalysis business. A subsequent confirmatory assignment, disclosed in a Form 8-K filed on April 29, 2026, further addressed intellectual property associated with the company's platform.
The company believes that the Asset Purchase Agreement transferred underlying technology, methodologies, computational approaches, and related intellectual property. Therefore, research activities by Kulkarni, whether directly or through Quantumzyme LLP, that relate to the company's core field and are based on or derived from the transferred technology fall within the scope of rights transferred to Quantum Genesis AI. The company's prior disclosures were made based on its ownership of relevant intellectual property.
This clarification is important for investors and stakeholders to accurately assess the company's technology assets and avoid confusion about its relationship with Quantumzyme LLP. The statement underscores the company's commitment to transparency and responsible corporate governance. For more information, visit qgaicorp.com and the company's profile on OTC Markets.
